Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olomorasib + carbamazepine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Olomorasib + carbamazepine** is a hypothetical combination of olomorasib, a potent, highly selective, second-generation small molecule inhibitor targeting the KRAS G12C mutation, and carbamazepine, an established anticonvulsant commonly used to treat epilepsy and neuropathic pain. Olomorasib irreversibly binds mutant KRAS G12C, inhibiting downstream oncogenic MAPK signaling in cancers such as non-small cell lung cancer (NSCLC). Carbamazepine acts as a voltage-gated sodium channel blocker, stabilizing neuronal membranes and reducing synaptic transmission. As of now, there is no reported clinical or preclinical development or usage of this specific combination, and no efficacy, safety, or rationale for pairing these drugs has been described in scientific literature or clinical trials[1][2][3][4][5].
- Other names
- olomorasib + carbamazepine
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)HRAS (H-Ras protein)NRAS G12CCYP3A4 (Cytochrome P450 3A4)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on olomorasib + carbamazepine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olomorasib + carbamazepine.